EPICOVIDEHA registry: Epidemiology and outcomes in patients with hematologic malignancies infected with COVID-19

Patients with hematologic malignancies (HMs) may have intensified immune dysregulation...

Severity of SARS-CoV-2 infection and the safety of COVID-19 vaccination in patients receiving HSCT

The coronavirus pandemic has put a great strain on worldwide healthcare systems. Patients with...

Fungal superinfections and COVID-19 in the ICU

The COVID-19 pandemic has caused a worldwide healthcare crisis. In addition to the morbidity caused by the initial infection, severely ill patients are...

When is it safe to schedule an allo-HSCT after COVID-19 infection?

During the virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to...

The latest on venetoclax combinations in AML from ASH 2021

The BCL-2 inhibitor, venetoclax, has transformed the treatment landscape for acute myeloid leukemia (AML), particularly in cases where...

Efficacy and safety of eprenetapopt (APR-246) combined with azacitidine in patients with TP53-mutant MDS and oligoblastic AML

Around 20% of patients with myelodysplastic syndromes (MDS) or acute...

How could new treatment combinations improve outcomes in TP53 mutant AML?

During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the AML Hub spoke to Naval Daver, MD Anderson Cancer...

Outcomes of decitabine and venetoclax treatment in mutant TP53 AML vs wild-type TP53 AML

TP53 is a tumor suppressor gene which protects cells against stress and is seen as the guardian of the genome...

Efficacy and safety of eprenetapopt (APR-246) combined with azacitidine in patients with TP53-mutant MDS and oligoblastic AML

Around 20% of patients with myelodysplastic syndromes (MDS) or acute...

The efficacy and safety of ofatumumab plus prednisone in cGvHD

Improved understanding of the pathophysiology of chronic graft-versus-host disease (cGvHD) has led to new opportunities for frontline...

Venetoclax with intensive chemotherapy for younger patients with ND AML, or MDS

Intensive chemotherapy regimens have been the mainstay of newly diagnosed (ND) acute myeloid leukemia (AML) induction...

Post-transplant maintenance therapy: low dose decitabine + venetoclax is safe and effective for high-risk AML and MDS

Both acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are...

EPICOVIDEHA registry: Epidemiology and outcomes in patients with hematologic malignancies infected with COVID-19

Patients with hematologic malignancies (HMs) may have intensified immune dysregulation...

QUAZAR AML-001: Update from EHA2021 on survival outcomes according to NPM1 and FLT3 gene mutational status at diagnosis

Oral azacitidine (oral-AZA; CC-486) has been approved by both the U.S. Food and...

Sabatolimab for the treatment of poor prognosis myelodysplastic syndromes and acute myeloid leukemia

High-risk and very high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) carry...

An overview of EHA guidelines for the use of antifungal prophylactic agents in acute myeloid leukemia

With increasing diversity of advances in the treatment of acute myeloid leukemia (AML), the need...